SequelSEC

MIRA PHARMACEUTICALS, INC. MIRA

Pharmaceutical Preparations · CIK 0001904286

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

MIRA PHARMACEUTICALS, INC. (MIRA) reported net income of -$10.44M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from MIRA PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MIRA PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailable
Net income-$10.44M-$7.85M-$11.98M-$7.06M
Research & development$1.72M$3.31M$1.57M$2.35M
Weighted-average diluted sharesUnavailableshares 15.44Mshares 13.92Mshares 17.57M
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.35$-0.51$-0.85$-0.40
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$8.77M$4.71M$6.50M$2.99M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

MIRA PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$6.35M$2.83MUnavailableUnavailable
Total assets$11.09M$2.92M$4.93M$858.07K
Current assets$11.06M$2.89M$4.86M$494.40K
Total liabilities$702.07K$723.35K$558.10K$1.45M
Current liabilities$702.07K$723.35K$558.10K$1.37M
Total equity incl. NCI$10.39M$2.20M$4.37M-$596.23K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$5.00K$5.00KUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$129.20K$723.35K$538.56KUnavailable

Cash flow

MIRA PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$4.66M-$5.56M-$4.53M-$5.60M
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailable
Financing cash flow$8.18M$3.79M$8.78M$3.15M
Net change in cash$3.51M-$1.77M$4.25M-$2.46M
Stock-based compensation$6.31M$1.92M$2.55M$1.30M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

MIRA PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio15.75x3.99x8.70x0.36x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MIRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.